

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JINTIAN PHARMACEUTICAL GROUP LIMITED

金天醫藥集團股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

POSITIVE PROFIT ALERT

This announcement is made by the Board of the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that based on the information currently available to the Board, the Group expects to record a substantial increase in its consolidated net profit for the six months ended 30 June 2014 as compared to that for the corresponding period in 2013.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

This announcement is made by the board of directors (the “**Board**”) of Jintian Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the information currently available to the Board, the Group expects to record a substantial increase in its consolidated net profit for the six months ended 30 June 2014 as compared to that for the corresponding period in 2013, which is mainly attributable to a substantial growth in both the retail and distribution businesses.

The Company is still in the process of finalising the interim results for the six months ended 30 June 2014. The information contained in this announcement is only based on a preliminary assessment by the Company’s management of the unaudited consolidated management accounts of the Group and is

not based on any figures or information that have been audited or reviewed by the auditors of the Company, and may be subject to amendments. Financial information and other details of the Group will be disclosed in the forthcoming interim results announcement which is expected to be published by the end of August 2014.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Jintian Pharmaceutical Group Limited
Jin Dongtao
Chairman

Hong Kong, 4 August 2014

As of the date of this announcement, the Board comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Chu Chuanfu and Ms. Wu Qiong and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Chen Ziao.